Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Darolutamide Maintains Efficacy in Patients with Comorbidities, Concomitant Medications in Nonmetastatic CRPC

February 18th 2022

The androgen receptor inhibitor darolutamide demonstrated continued efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have comorbidities or concomitant medications

Continuous Enzalutamide After Progression Improves PFS in Patients with mCRPC

February 18th 2022

Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone

Darolutamide Plus ADT Boosts OS in Metastatic Castration-Sensitive Prostate Cancer

February 18th 2022

The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.

Frontline Niraparib Plus Abiraterone Improves rPFS in HRR Gene–Altered mCRPC

February 17th 2022

The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC

February 17th 2022

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

Deep PSA Response Is Associated with Positive Wellbeing Scores in Advanced Prostate Cancer

February 17th 2022

Treatment with apalutamide, an androgen receptor inhibitor, was associated with a deep PSA response leading to beneficial outcomes in patient-related end points.

Apalutamide Outperforms Enzalutamide in mCSPC in Real-World Analysis

February 17th 2022

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

Dr. Saad on the Efficacy of First-Line Olaparib Plus Abiraterone in mCRPC

February 17th 2022

Fred Saad, MD, FRCS, discusses the efficacy of olaparib plus abiraterone acetate as first-line treatment in metastatic castration-resistant prostate cancer.

Dr. Merseburger on the Efficacy of Continuing Enzalutamide in mCRPC

February 17th 2022

Axel Merseburger, MD, PhD, discusses results from the phase 3b PRESIDE trial in metastatic castration-resistant prostate cancer.

Dr. Armstrong on Findings From a Post-Hoc Analysis of the ARCHES Trial in mHSPC

February 17th 2022

Andrew J. Armstrong, MD, MSc, discusses findings from a post-hoc analysis of the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Dr. Tewari on the Factors to Consider for Robotic Radical Prostatectomy in Prostate Cancer

February 16th 2022

Ashutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy for a patient with prostate cancer.

FDA Grants Breakthrough Status to TriNetra-Prostate Blood Test to Detect Early-Stage Prostate Cancer

February 15th 2022

The FDA has granted a breakthrough device designation to the TriNetra-Prostate blood test for use in the detection of early-stage prostate cancer.

Dr. Sharifi on Methodologies Utilized to Evaluate Link Between Gut Microbiome and Fatal Prostate Cancer

February 14th 2022

Nima Sharifi, MD, director, discusses the methodologies utilized when evaluating the correlation between gut microbiome and fatal prostate cancer.

Molecular Differences Contribute to Disparity Between Black and White Patients with Prostate Cancer

February 10th 2022

Dhyan Chandra, PhD, discusses recent findings relating to low levels of cytochrome C in Black men with prostate cancer, plus plans for future research on this topic.

Dr. Sharifi on the Rationale to Evaluate the Correlation Between the Gut Microbiome and Aggressive Prostate Cancer

February 10th 2022

Nima Sharifi, MD, discusses the rationale to evaluate the correlation between the gut microbiome and the aggressiveness of prostate cancer.

Dr. Woloszynska on the Role of Community Outreach in Addressing Disparities in Prostate Cancer

February 9th 2022

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

Dr. Chandra on the Need for Resources to Evaluate Racial Disparities in Prostate Cancer

January 28th 2022

Dhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.

Dr. LeBeau on the Potential Applicability of Shark Antibodies in Prostate Cancer

January 27th 2022

Aaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.

Dr. Woloszynska on Continued Research Efforts Investigating Racial Disparities in Prostate Cancer

January 26th 2022

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

Dr. Chandra on Evaluating Biological Differences in African Americans With Prostate Cancer

January 24th 2022

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.